The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.
NF-kappaB transcription factors have key roles in inflammation, immune response, oncogenesis and protection against apoptosis. In most cells, these factors are kept inactive in the cytoplasm through association with IkappaB inhibitors. After stimulation by various reagents, IkappaB is phosphorylated by the IkappaB kinase (IKK) complex and degraded by the proteasome, allowing NF-kappaB to translocate to the nucleus and activate its target genes. Here we report that CYLD, a tumour suppressor that is mutated in familial cylindromatosis, interacts with NEMO, the regulatory subunit of IKK. CYLD also interacts directly with tumour-necrosis factor receptor (TNFR)-associated factor 2 (TRAF2), an adaptor molecule involved in signalling by members of the family of TNF/nerve growth factor receptors. CYLD has deubiquitinating activity that is directed towards non-K48-linked polyubiquitin chains, and negatively modulates TRAF-mediated activation of IKK, strengthening the notion that ubiquitination is involved in IKK activation by TRAFs and suggesting that CYLD functions in this process. Truncations of CYLD found in cylindromatosis result in reduced enzymatic activity, indicating a link between impaired deubiquitination of CYLD substrates and human pathophysiology.
Pubmed ID: 12917691 RIS Download
Amino Acid Sequence | Catalysis | Cell Line | Humans | I-kappa B Kinase | Molecular Sequence Data | Mutation | NF-kappa B | Protein Binding | Protein-Serine-Threonine Kinases | Proteins | RNA, Small Interfering | Signal Transduction | Substrate Specificity | TNF Receptor-Associated Factor 2 | Tumor Suppressor Proteins | Ubiquitin